Supriya Lifesci. Q1 FY27 Earnings Call — Analysis (NSE: SUPRIYA)
Supriya Lifescience Q1FY27 revenue grew 31% YoY to ₹190 Cr but EBITDA margin contracted to 25% due to one-off water and power headwinds, while full-year guidance of ~₹1,000 Cr revenue and 33-35% EBITDA margin is reiterated.
Result quality: watch — Margin pressure. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹190 Cr ( +31% YoY ) . New guidance — FY27 fy27 revenue ₹1,000 Cr . New story: Temporary headwinds, guidance reaffirmed .
Results
Revenue ₹190 Cr +31% YoY; EBITDA ₹47 Cr -8.1% YoY; EBITDA margin 25%.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹190 Cr | +31% | yoy · Q1FY27 · vs Q1FY26 |
| EBITDA | ₹47 Cr | −8.1% | yoy · Q1FY27 · vs Q1FY26 |
| EBITDA Margin | 25% | +na | point_in_time · Q1FY27 · Q1FY27 |
| PAT | ₹24 Cr | yoy · Q1FY27 · vs ₹35 Cr in Q1FY26 | |
| PAT Margin | 12.7% | +na | point_in_time · Q1FY27 · Q1FY27 |
| Export Contribution | 81% | +na | point_in_time · Q1FY27 · of Q1FY27 revenue |
Guidance
FY27 revenue target of ~₹1,000 Cr and EBITDA margin 33-35% reiterated despite Q1 headwinds; management expects non-linear quarterly growth and recovery of lost sales.
What management committed to
- Supriya Lifescience will achieve revenue of ~₹1,000 Cr in FY27. — ₹1,000 Cr, FY27
- Supriya Lifescience will maintain EBITDA margins in the range of 33% to 35% in FY27. — 33% to 35%, FY27
- Contrast media products will be launched in H2FY27. — H2FY27
- The EU audit of [Ambernath] facility will take place in the second half of November 2026. — Q3FY27
- A term sheet for a large anesthetic CDMO contract will be signed and announced in the next quarter (Q2FY27). — Q2FY27
- Supriya Lifescience will receive the CEP certificate for [anesthetic API] between October and November 2026. — Q3FY27
- Patalganga Phase-1 will achieve 40% completion within 2.5 years from land acquisition. — 40%, 2.5 years from acquisition
- Phase-1 capex for Patalganga facility will be around ₹200 Cr. — ₹200 Cr
- Ambernath facility will start contributing to revenue in FY27. — FY27
- Supriya Lifescience will grow at a CAGR of about 20% beyond FY27. — 20%, beyond FY27
- Q2 FY27 production will not be impacted in any major way by the maintenance shutdown, as it will be done in a phased manner. — Q2FY27
- The elevated inventory of ₹230-240 Cr will be liquidated over the next three to four quarters. — next three to four quarters
Key themes
Temporary disruptions, guidance intact; pipeline and capacity expansion.
How the narrative shifted
- Temporary headwinds, guidance reaffirmed: Management frames the Q1 margin miss as a one-off from water scarcity and solar policy changes, emphasizing that underlying demand is strong and full-year top-line and margin targets remain firmly on track.
- Regulatory approvals as growth catalyst: The company positions near-term regulatory milestones—EU audit at Ambernath in November 2026, CEP for anesthetic API—as key unlocks for Ambernath ramp-up and EU regulated market access.
- Product pipeline acceleration: New product launches (contrast media H2FY27, anesthetic liquid inhalation, ADHD pipeline) are expected to drive second-half acceleration and sustain the 20% CAGR.
- CDMO/CMO pivot as long-term vertical: Management is actively building a CDMO/CMO business, with a term sheet close for a large anesthetic contract, and projects Ambernath to become a key CMO-driven site, eventually making CDMO one of the strongest verticals.
- Capacity expansion and de-risking: The company is investing in Patalganga greenfield (₹200 Cr Phase-1) and Lote enhancements to overcome capacity constraints, while cancelling a major shutdown to protect Q2 production.
- Inventory overhang normalization: Inventory built up to ₹230-240 Cr in anticipation of a shutdown that is now cancelled; management plans to liquidate over 3-4 quarters.
- Export mix shift to regulated markets: Export contribution remains high at 81%, with Asia and Europe leading; North America contribution is rising as DMFs convert, and the company is relatively insulated from US tariff threats due to Europe focus.
Operational commentary
- Water shortage at Lote MIDC due to delayed monsoon resolved; deferred ~₹35 Cr sales in Q1, no recurrence expected.
- Planned annual maintenance shutdown for Blocks A-D in August cancelled; phased debottlenecking to avoid production impact.
- Two new anesthetic liquid inhalation products launched in Q2FY27 from Ambernath; expected to scale up.
- Contrast media products on track for launch in H2FY27.
- EU audit of Ambernath facility scheduled for second half of November 2026, a key regulatory unlock.
- Patalganga greenfield Phase-1 started (boundary wall); ₹200 Cr capex for API blocks and utilities, first focus on API to supplement Lote capacity.
- Large anesthetic CDMO contract close to signing term sheet; qualification work completed.
- DSM contract (vitamin) pharma validation completed, dedicated facility operational, near peak volumes.
- Cardiovascular product launched in Q3FY26 ramping well, commercialized; full effect expected in 9-12 months.
- Anesthetic API filings: CEP expected Oct-Nov 2026; EU audit to boost regulated market sales.
- North America: DMFs filed, customers picking up volumes for validation.
- SAP implementation underway, go-live in 4-5 months; TrackWise QMS already implemented.
- Inventory built up to ₹230-240 Cr ahead of cancelled shutdown; will be liquidated over next 3-4 quarters.
- Export authorization technical lapse on a single small consignment, new permit obtained; matter sub judice, no provision made.
- Backward integration at 72% of total revenues; revenue mix shift contributed to margin dip.
- R&D team expanded to ~70 people; new R&D at Ambernath for API and formulations.
Analyst Q&A
Q. What is the timeline for Patalganga Phase-1 and why the delay in breaking ground?
Boundary wall construction has started, so ground is broken. Phase-1 will focus on API block with utilities; ₹200 Cr investment. As per MIDC, 40% completion required in ~2.5 years from acquisition.
Q. When will the EU audit at Ambernath happen and when can regulated market revenues begin?
We have received the audit dates; the EU audit is scheduled for the second half of November 2026.
Q. Will the water shortage and solar power cost impact recur in Q2, and is the full-year guidance still valid?
Water issue resolved; retrospective solar cost is one-time. Operational cost increases will be passed on. FY27 revenue ~₹1,000 Cr and EBITDA margin 33-35% guidance remains intact.
Q. Update on the large CMO contracts and CDMO progress?
We are very close to signing a term sheet for a large anesthetic CDMO contract; qualification work is completed. We expect to announce something good in the next quarter.
Q. Can you provide revenue contribution and margin details for the cardiovascular product?
We will not be able to talk in detail about individual product contribution. Volume pickup is good, but for it to be a larger contributor it will take at least 9-12 months.
Research and educational content only. Not investment advice.